As of 2025-07-05, the EV/EBITDA ratio of Altimmune Inc (ALT) is -7.13. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 698.77 mil USD. Altimmune's TTM EBITDA according to its financial statements is -97.96 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.3x - 12.8x | 11.0x |
| Forward P/E multiples | 20.6x - 33.3x | 27.0x |
| Fair Price | (12.53) - (7.67) | (11.53) |
| Upside | -363.3% - -261.1% | -342.3% |
| Date | EV/EBITDA |
| 2025-07-03 | -7.13 |
| 2025-07-02 | -7.36 |
| 2025-07-01 | -6.28 |
| 2025-06-30 | -5.71 |
| 2025-06-27 | -5.11 |
| 2025-06-26 | -5.29 |
| 2025-06-25 | -11.86 |
| 2025-06-24 | -11.03 |
| 2025-06-23 | -10.71 |
| 2025-06-20 | -10.77 |
| 2025-06-18 | -10.37 |
| 2025-06-17 | -10.55 |
| 2025-06-16 | -10.52 |
| 2025-06-13 | -10.60 |
| 2025-06-12 | -10.97 |
| 2025-06-11 | -9.99 |
| 2025-06-10 | -10.31 |
| 2025-06-09 | -9.04 |
| 2025-06-06 | -8.51 |
| 2025-06-05 | -8.26 |
| 2025-06-04 | -8.30 |
| 2025-06-03 | -8.19 |
| 2025-06-02 | -8.00 |
| 2025-05-30 | -8.21 |
| 2025-05-29 | -8.50 |
| 2025-05-28 | -8.30 |
| 2025-05-27 | -8.34 |
| 2025-05-23 | -8.66 |
| 2025-05-22 | -8.75 |
| 2025-05-21 | -8.46 |
| 2025-05-20 | -8.88 |
| 2025-05-19 | -8.32 |
| 2025-05-16 | -8.45 |
| 2025-05-15 | -8.77 |
| 2025-05-14 | -8.64 |
| 2025-05-13 | -8.74 |
| 2025-05-12 | -9.14 |
| 2025-05-09 | -8.46 |
| 2025-05-08 | -8.80 |
| 2025-05-07 | -8.10 |
| 2025-05-06 | -7.57 |
| 2025-05-05 | -8.21 |
| 2025-05-02 | -8.75 |
| 2025-05-01 | -7.79 |
| 2025-04-30 | -7.92 |
| 2025-04-29 | -7.68 |
| 2025-04-28 | -7.61 |
| 2025-04-25 | -7.63 |
| 2025-04-24 | -7.79 |
| 2025-04-23 | -7.47 |